Assessment of Pruritus Improvement With Pimecrolimus Treatment on the Areas Affected by Mild-to-moderate AD, in Patients 2- to 11- Year-old
- Conditions
- Atopic Dermatitis
- First Posted Date
- 2007-08-01
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 117
- Registration Number
- NCT00510003
- Locations
- 🇪🇸
Novartis Investigative Site, Madrid, Spain
Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors
- Conditions
- Advanced Neuroendocrine Tumors of Pancreatic Origin
- Interventions
- First Posted Date
- 2007-08-01
- Last Posted Date
- 2015-07-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 410
- Registration Number
- NCT00510068
- Locations
- 🇺🇸
University of South Alabama / Mitchell Cancer Institute Deptof Mitchell Cancer Inst(2), Mobile, Alabama, United States
🇺🇸Pacific Cancer Medical Center, Inc., Anaheim, California, United States
🇺🇸University of Texas/MD Anderson Cancer Center Dept of MD Anderson CancerCent, Houston, Texas, United States
Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China
- First Posted Date
- 2007-07-27
- Last Posted Date
- 2021-09-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 52
- Registration Number
- NCT00508274
- Locations
- 🇭🇰
Novartis Investigative Site, Shatin, Hong Kong
Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline
- Conditions
- Alzheimer Disease
- Interventions
- Drug: Placebo to 15 cm^2 patchDrug: Placebo to 10 cm^2 patch
- First Posted Date
- 2007-07-25
- Last Posted Date
- 2012-09-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1584
- Registration Number
- NCT00506415
- Locations
- 🇺🇸
Novartis Investigative Site, Honolulu, Hawaii, United States
🇨🇭Novartis investigative site, Mendrisio, Switzerland
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QAU145 in Patients With Cystic Fibrosis
- First Posted Date
- 2007-07-25
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 9
- Registration Number
- NCT00506792
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
Efficacy, Safety and Tolerability of AEB071 Versus Cyclosporine in the Novo Renal Transplant Recipients
- First Posted Date
- 2007-07-20
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 311
- Registration Number
- NCT00504543
- Locations
- 🇦🇷
Argentina, Buenos Aires, Argentina
🇧🇪Belgium, Gent, Belgium
🇨🇳Novartis Investigative Site, Taipie, Taiwan
A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid Tumors
- First Posted Date
- 2007-07-18
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 14
- Registration Number
- NCT00503451
- Locations
- 🇺🇸
Nevada Cancer Institute, Las Vegas, Nevada, United States
🇳🇱Novartis Investigative Site, Rotterdam, Netherlands
Efficacy and Safety of Four Doses of Glycopyrronium Bromide (NVA237) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), in Comparison to an Active Comparator Tiotropium
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2007-07-16
- Last Posted Date
- 2012-05-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 83
- Registration Number
- NCT00501852
- Locations
- 🇯🇵
Novartis Investigator site, Tokyo, Japan
🇫🇷Novartis Investigator Site, Rueil-Malmaison,, France
Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone
- First Posted Date
- 2007-06-28
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 16
- Registration Number
- NCT00493766
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Nevada Cancer Institute, Las Vegas, Nevada, United States
🇺🇸Washing University School of Medicine, Saint Louis, Missouri, United States
Efficacy and Safety of AEB071 Versus Tacrolimus in Combination With Mycophenolate Acid Sodium, Basiliximab and Steroids in Preventing Acute Rejection After Kidney Transplantation
- Conditions
- Kidney Transplantation
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 124
- Registration Number
- NCT00492869
- Locations
- 🇺🇸
USC Medical Center, Los Angeles, California, United States
🇺🇸University of Cincinnati, Dept of Internal Medicine, Cincinnati, Ohio, United States
🇺🇸University of Colorado Health Science Center, Denver, Colorado, United States